share_log

復星醫藥：股東周年大會通告

FOSUN PHARMA: NOTICE OF ANNUAL GENERAL MEETING

HKEX ·  May 24 16:33

Summary by Moomoo AI

上海復星醫藥（集團）股份有限公司（「復星醫藥」）將於2024年6月26日下午一時三十分在中國上海市舉行股東周年大會。會議將審議及批准包括2023年年度報告、董事會及監事會工作報告、財務決算報告、利潤分配預案在內的多項普通決議案。此外，會議還將審議續聘安永華明會計師事務所及安永會計師事務所為2024年度財務報告審計機構，並通過其報酬方案。特別決議案包括授權董事會發行A股及╱或H股股份的一般性授權，以及回購H股及A股股份的一般性授權。股東將審議修訂《公司章程》及其附件。股東出席資格的登記將於2024年6月21日至6月26日暫停。復星醫藥董事長吳以芳將主持會議。
上海復星醫藥（集團）股份有限公司（「復星醫藥」）將於2024年6月26日下午一時三十分在中國上海市舉行股東周年大會。會議將審議及批准包括2023年年度報告、董事會及監事會工作報告、財務決算報告、利潤分配預案在內的多項普通決議案。此外，會議還將審議續聘安永華明會計師事務所及安永會計師事務所為2024年度財務報告審計機構，並通過其報酬方案。特別決議案包括授權董事會發行A股及╱或H股股份的一般性授權，以及回購H股及A股股份的一般性授權。股東將審議修訂《公司章程》及其附件。股東出席資格的登記將於2024年6月21日至6月26日暫停。復星醫藥董事長吳以芳將主持會議。
SHANGHAI FUSTAR PHARMACEUTICALS (GROUP) CO., LTD. (“FUSTAR PHARMACEUTICALS”) WILL HOLD ITS ANNUAL GENERAL MEETING ON 26 JUNE 2024 AT 1:30 P.M. IN SHANGHAI, CHINA. The meeting will review and approve a number of general resolutions including the 2023 Annual Report, the Board and Board of Supervisors work report, the Financial Decision Report, and the Profit Distribution Forecast. In addition, the meeting will discuss the renewal of EY and EY Accounting Firm as financial report audit bodies for 2024 and approve their remuneration plans. The Special Resolution includes an authorization for the Board of Directors to issue A shares and/or shares of H shares and general authorizations to repurchase H shares and A shares. Shareholders will discuss amendments to the Articles of Association and their annexes. Registration of the right of shareholders to attend will be suspended from 21 June to 26 June 2024. FUSTAR PHARMACEUTICALS CHAIRMAN WU YIFANG WILL CHAIR THE MEETING.
SHANGHAI FUSTAR PHARMACEUTICALS (GROUP) CO., LTD. (“FUSTAR PHARMACEUTICALS”) WILL HOLD ITS ANNUAL GENERAL MEETING ON 26 JUNE 2024 AT 1:30 P.M. IN SHANGHAI, CHINA. The meeting will review and approve a number of general resolutions including the 2023 Annual Report, the Board and Board of Supervisors work report, the Financial Decision Report, and the Profit Distribution Forecast. In addition, the meeting will discuss the renewal of EY and EY Accounting Firm as financial report audit bodies for 2024 and approve their remuneration plans. The Special Resolution includes an authorization for the Board of Directors to issue A shares and/or shares of H shares and general authorizations to repurchase H shares and A shares. Shareholders will discuss amendments to the Articles of Association and their annexes. Registration of the right of shareholders to attend will be suspended from 21 June to 26 June 2024. FUSTAR PHARMACEUTICALS CHAIRMAN WU YIFANG WILL CHAIR THE MEETING.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated